Biosimulation Market: Growth, Size, Share, and Trends

Report Code HIT 3629
Published in Jan, 2025, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Biosimulation Market by Offering (Module, Integrated Platform), Application (Disease Modeling, PBPK, PKPD, Trial Simulation, Manufacturing & Supply chain: planning & forecasting), Indication (Cancer, CNS, CVS), End User, & Region - Global Forecast to 2029

Updated on : January 29, 2025

Market Growth Outlook Summary

The global biosimulation market, valued at US$3.64 billion in 2023, is forecasted to grow at a robust CAGR of 16.7%, reaching US$4.24 billion in 2024 and an impressive US$9.18 billion by 2029. The market is experiencing significant growth, driven by increasing R&D investments in the pharmaceutical and biotech industries. Biosimulation facilitates the drug discovery and development process through predictive modeling of biological systems, making it easier to evaluate a drug’s safety and efficacy. This approach reduces drug discovery time and costs by minimizing experimental work and optimizing clinical trial design. AI-integrated biosimulation platforms, such as Orion by OpenEye, Cadence Molecular Sciences, and the BIOiSIM platform by VeriSIM Life, offer enhanced accuracy and efficiency, leading to improved predictions in drug development.

Biosimulation Market – Global Forecast and Key Opportunities to 2029

Biosimulation Market – Global Forecast and Key Opportunities to 2029

Asia Pacific

The Asia Pacific biosimulation market is experiencing significant growth driven by rising R&D investments and a growing burden of chronic diseases. Budget constraints push healthcare providers to adopt cost-effective solutions, while the region's expanding biotechnology sector is further enhancing the demand for biosimulation tools.

Advancements in quantitative systems pharmacology (QSP) help build better biosimulation models to drive the market significantly.

Emerging applications of biosimulation in precision medicine, biopharmaceuticals, and toxicology are expected to provide lucrative opportunities for market players.

The North America market is expected to be worth USD 3.21 billion by 2029, growing at a CAGR of 14.4% during the forecast period.

The absence of standardized protocols for biosimulation model representation poses a challenge for collaboration and scalability, limiting market growth opportunities.

Biosimulation Market Dynamics to 2029

DRIVER: Growing adoption of biosimulation software by regulatory bodies

Regulatory agencies around the world, like the US FDA, the European Medicines Agency (EMA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), use biosimulation software to improve drug safety and evaluate effectiveness. These tools help to speed up the drug approval process by identifying any sort of potential issues with the new drugs, which saves time and cost involved in the process. In December 2021, the US FDA renewed and expanded its licenses for Certara's biosimulation software, now holding over 400 user licenses for Simcyp and Phoenix software. This expansion allowed the FDA to simulate drug behavior in virtual patient populations, to assess potential drug-drug interactions, and predict adverse effects more effectively. Additionally, the EMA has endorsed in silico approaches to streamline drug evaluations, contributing to the growing market demand for these technologies.

RESTRAINT: Data Availability and Quality

The effectiveness of biosimulation models heavily depend on the quality and comprehensiveness of the data used to develop them. Insufficient or low-quality data can result in unreliable predictions and incorrect simulations. The required chemical, biological, or clinical data is often incomplete or unavailable, especially in the case of rare diseases or novel drug compounds. For instance, if clinical trial data from earlier phases is incomplete or if real-world data (RWD) lacks proper validation, then the biosimulation outcomes may not accurately give real-world drug performance. When tapping such scenarios, the authenticity of the data used is of prime importance. Established market players often have access to large datasets and libraries of data, but for newer players entering the market, it is challenging to get access to such databases, requiring large investments in the initial phase.

 

OPPORTUNITY: Use of biosimulation solution for pediatric drug development

Pediatric populations are very different from adults in physiology and drug responses, which complicates clinical trial design. Biosimulation bridges this gap with virtual models that simulate drug interactions in children at various developmental stages and reduce the need for extensive clinical trials. For instance, Simcyp Pediatric by Certara is a platform that allows researchers to model pharmacokinetics and pharmacodynamics (PK/PD) by inputting the variables such as age and weight, to optimize the dosing and predict adverse effects. Recently, the FDA published an “Integrate-Simulate-Optimize” workflow for employing Model-Informed Drug Development (MIDD), which emphasizes understanding disease pathophysiology and extrapolating data from adult populations or other pediatric groups to enhance pediatric drug development efforts.

CHALLENGES: Difficulty in matching the complexity of biological systems and processes

Matching the complexity of biological systems and processes is a major challenge for the simulators and modelers. This is because biological processes are complex structures with many pathways interrelating to one another. Biological systems are dynamic in nature; hence, they can change rapidly in response to various stimuli, making it difficult to develop adaptive models that accurately predict long-term outcomes. The individual variability in genetics and physiology adds another layer of complexity to this challenge. Generating a high-fidelity simulation requires significant computational resources, which increases the need for advanced infrastructure. A successful biosimulation relies on effective collaboration between biologists, mathematicians, and computer scientists, but this interdisciplinary collaboration may sometimes pose a challenge as well.

Biosimulation Market Map & Ecosystem Overview

The biosimulation ecosystem includes software providers, pharmaceutical and biotech companies, regulatory agencies, academic institutions, and contract research organizations (CROs). The interaction among these players shapes the development, adoption, and advancement of biosimulation technologies.

The key stakeholders in this market include Healthcare IT Service Providers, Biosimulation Vendors, Clinical Research Organizations, Pharmaceutical/Biopharmaceutical Companies, Research and Development (R&D) Companies, Business Research and Consulting Service Providers, Medical Research Laboratories, Academic Medical Centers/Universities/Hospitals, Regulatory Agencies, Clinical Researchers, Clinical Research Organizations, Investors and Venture Capitalists.

Solution providers in the market develop and cater biosimulation software and services, such as PBPK, PK/PD simulation software, molecular modeling and simulation software, toxicity prediction software, and trial design software, based on the customer’s requirements, whereas the services offered consist of consulting & advisory, implementation, training & support, and data analysis & interpretation services.

Biosimulation Market Ecosystem

Source: Secondary Literature, Interviews with Experts, and MarketsandMarkets Analysis

 

The global biosimulation market is segmented on the basis of offering, application, therapeutic area, revenue model, deployment model, end user, and region.

By offering, the software segment accounted for the largest share of the biosimulation market in 2023

By offering, the biosimulation market is segmented into software and services. The software segment held the largest share of the biosimulation market in 2023. This segment is categorized into standalone modules and integrated software suites/platforms. The standalone platforms are divided into molecular modeling & simulation software, PBPK modeling & simulation software, PK/PD modeling & simulation software, clinical trial simulation software, toxicity prediction software, and other biosimulation software.

The large share of the software segment can be attributed to the extensive efforts of pharmaceutical and biotech companies in drug discovery and development. More and more companies are putting efforts and capital into drug discovery. As of 2023, the US FDA approved a total of 55 new drugs, including 17 biologics, 9 TIDES (5 peptides and 4 oligonucleotides), and 29 small molecules. The use of biosimulation accelerates the drug discovery & development process while reducing the associated costs. According to the JAMA Network, the R&D cost for developing a new drug is estimated to range from USD 314 million to USD 4.46 billion. Use of biosimulation and modeling tools help improve the overall efficiency of the drug discovery and development process.

Oncology segment to hold the largest share in the biosimulation market by therapeutic area

Based on therapeutic area, the Biosimulation market is segmented into oncology, cardiovascular disease, neurological disorders, infectious diseases and other therapeutic areas. The oncology market dominated the biosimulation market in 2023 and is poised to grow significantly during the forecast period. The World Health Organization, in 2022, stated around 20 million new cancer cases and 9.7 million deaths, highlighting the need for effective therapies. Biosimulation is of critical importance as scientists and researchers can now model tumor biology and predict drug response and dosing regimens for chemotherapy, targeted therapies, and immunotherapies. As of October 2024, the US FDA has approved a total of 48 drugs and therapies for oncology/hematologic malignancies. The FDA, in this regard, has also launched an initiative called Project Optimus aimed at reforming dose optimization and selection in oncology drug development to enhance both the efficacy and safety profiles of novel therapies. This project promotes early cooperation between drug developers and the FDA in an improved communication, workshops, and data-driven strategy to carry out effective dose-finding evaluations. The players like Certara, Cellworks, OpenEye, Cadence Molecular Sciences are further focusing on the discovery and development of safer cancer therapies.

The on-premises model accounted for the largest share of the biosimulation market in 2023, by deployment type

Based on the deployment model, the biosimulation market is segmented into on-premises, cloud-based, and hybrid models. On-premises biosimulation models are driven by several key factors that cater to the specific needs of organizations. Data security is a significant concern, as many companies prefer to maintain control over sensitive information to comply with regulatory requirements and protect intellectual property. Additionally, on-premises solutions allow for extensive customization to fit unique organizational workflows, providing greater flexibility in model development.

However, cloud-based models are set to record the fastest growth during the forecast period owing to its scalability, providing ease of access to the users without heavy upfront investments in infrastructure. Some of the software offering cloud-based deployment include Phoenix by Certara, Maestro by Schrödinger, BIOVIA by Dassault Systèmes, and Orion by OpenEye, Cadence Molecular Sciences.

North America accounted for the largest share of the Biosimulation market in 2023

The biosimulation market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2023, North America accounted for the highest share of the biosimulation market. This was driven by the strong biopharmaceutical sector, particularly in the US, where leading pharmaceutical and biotech companies increasingly adopt advanced modeling techniques to enhance drug discovery and development process. The region also witnesses a dominating presence of the majority of market players like Certara, Simulations Plus, Schrödinger, Inc., Advanced Chemistry Development, Inc., Chemical Computing Group ULC., Rosa & Co. LLC., and Genedata AG, among others. The pharmaceutical and biotechnology companies are investing a large share of their revenue in the expansion of their R&D capabilities, thus driving the demand for biosimulation tools in the region.

Moreover, the regulatory agencies like FDA are embracing biosimulation technologies in clinical studies. Collaborative efforts among academia, industry, and regulatory bodies further strengthens its application. The FDA through various initiatives, such as the Model-Informed Drug Development (MIDD) Paired Meeting Program, focuses on integrating exposure-based, biological, and statistical models into drug development and regulatory processes to enhance decision-making and optimize therapeutic outcomes.

HIGHEST CAGR MARKET IN 2023
US FASTEST GROWING MARKET IN THE REGION
Biosimulation Market Region

Biosimulation Market Recent Developments and Insights

  • In January 2025, Physiomics Plc announced that its personalized dosing software project, PREDICT-ONC, received both regulatory and ethical approvals, allowing the commencement of an observational clinical trial. This trial aims to recruit breast cancer patients undergoing standard G-CSF treatment to predict and measure treatment effects on neutropenia, thereby refining the software's predictive capabilities.
  • In January 2025, Schrödinger provided an update on its business progress and outlined strategic priorities for 2025. The company announced an expanded research collaboration agreement with Otsuka Pharmaceutical Co., Ltd., and highlighted plans to report initial Phase 1 data from three proprietary programs within the year. The focus remains on delivering continued software growth and increasing drug discovery revenue.
  • In February 2024, Dassault Systèmes announced major updates to its BIOVIA Discovery Studio Simulation platform, incorporating AI/ML models like AlphaFold2 and OpenFold for advanced protein structure prediction. These updates integrate cutting-edge AI with traditional physics-based modeling techniques, offering researchers more accurate tools for drug discovery.
  • In October 2024, Certara acquired Chemaxon to combine its expertise in biosimulation with Chemaxon's cheminformatics expertise. This acquisition will help Certara expand its capabilities to help life science companies enhance their productivity and boost scientific innovation success rates.
  • In September 2024, Advanced Chemistry Development (ACD/Labs) launched the version 2024 of its flagship Percepta platform, offering enhanced prediction accuracy for logP, logD, and pKa, and a range of ADME and toxicity endpoints, making the platform more robust and efficient.
  • In June 2024, Simulations Plus acquired Pro-ficiency, LLC, in a USD 100 million deal to expand its market reach. This acquisition tends to double Simulations Plus’s total addressable market to USD 8 billion by utilizing Pro-ficiency's AI-driven software and services.
  • In March 2024, Dassault Systèmes collaborated with CDR-Life Inc. to enhance the development of highly tumor-selective immunotherapies using CDR-Life’s M-gager platform. This collaboration allowed the contract research team of Dassault to perform virtual “what if” experiments on antibody-based biologics utilizing the BIOVIA software and CDR-Life’s experimental data.
  • In January 2023, Schrödinger announced its collaboration with Otsuka Pharmaceutical Co., Ltd. and its U.K.-based subsidiary Astex Pharmaceuticals to utilize Schrödinger’s drug design platform to pursue drug discovery research for CNS diseases. This collaboration allowed Otsuka to leverage its drug discovery and clinical development activities to expand its R&D pipeline.

Key Players Driving Growth in the Biosimulation Market

KEY PLAYERS IN THE BIOSIMULATION MARKET INCLUDE

Want to explore hidden markets that can drive new revenue in Biosimulation Market?

Scope of the Report

Report Metric Details
Market size available for years 2022–2029
Base Year Considered 2023
Forecast period 2024–2029
Forecast units Million/Billion (USD)
Segments covered Offerings, Applications, Therapeutic Area, Revenue Model, Deployment Model, and End-user
Geographies covered North America, Europe, Asia Pacific, Latin America, and Middle East Africa

Key Questions Addressed by the Report

The global biosimulation market is projected to grow from USD 4.24 billion in 2024 to USD 9.18 billion by 2029, demonstrating a robust CAGR of 16.7%.
Primary drivers for the biosimulation market include increasing R&D investments in pharmaceutical and biotech industries, and the growing adoption of biosimulation software by regulatory bodies to improve drug safety and efficacy.
The oncology therapeutic area holds the largest share of the biosimulation market, driven by the need for improved therapies and the increasing use of biosimulation in cancer drug development.
Challenges in the biosimulation market include the difficulty in matching the complexity of biological systems and processes, and issues with data availability and quality, especially for rare diseases or novel drug compounds.
North America accounted for the largest share of the biosimulation market in 2023, driven by the strong biopharmaceutical sector and increasing adoption of advanced modeling techniques in drug development.

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Biosimulation Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table Of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
35
RESEARCH METHODOLOGY
41
EXECUTIVE SUMMARY
54
PREMIUM INSIGHTS
60
MARKET OVERVIEW
64
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Increasing R&D investments in pharmaceutical and biotechnology industries
    - Growing adoption of biosimulation software by regulatory bodies
    - Integration of technologically advanced Quantitative Systems Pharmacology (QSP)
    - Need to curtail drug discovery and development costs
    - Growth in biologics and biosimilars markets
    RESTRAINTS
    - Lack of standardization
    - Data availability and quality
    OPPORTUNITIES
    - Emerging applications
    - Use of biosimulation solutions for pediatric drug development
    CHALLENGES
    - Difficulties in matching complexity of biological systems and processes
    - Shortage of biosimulation and modeling experts
  • 5.3 ECOSYSTEM ANALYSIS
    SOFTWARE PROVIDERS
    PHARMACEUTICAL & BIOTECH COMPANIES
    CONTRACT RESEARCH ORGANIZATIONS (CROS)
    REGULATORY BODIES
    ACADEMIC & RESEARCH INSTITUTIONS
  • 5.4 CASE STUDY ANALYSIS
    CASE STUDY 1: OPTIMIZING ASCIMINIB DEVELOPMENT THROUGH ADVANCED PBPK MODELING
    CASE STUDY 2: COMPUTATIONAL DISCOVERY OF SELECTIVE WEE1 INHIBITORS FOR CANCER
    CASE STUDY 3: EFFICIENT CLINICAL TRIAL UTILIZING SCALE MANAGEMENT EXPERTISE
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 PORTER'S FIVE FORCES ANALYSIS
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    THREAT OF SUBSTITUTES
    THREAT OF NEW ENTRANTS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.7 REGULATORY ANALYSIS
    REGULATORY LANDSCAPE
    - North America
    - Europe
    - Asia Pacific
    - Latin America
    - Middle East & Africa
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8 PATENT ANALYSIS
    PATENT PUBLICATION TRENDS FOR BIOSIMULATION
    JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.9 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Mathematical modeling
    - Software platforms
    - Quantitative systems pharmacology (QSP)
    COMPLEMENTARY TECHNOLOGIES
    - Data analytics
    - Machine learning and AI
    ADJACENT TECHNOLOGIES
    - In silico trials
  • 5.10 INDUSTRY TRENDS
    DISCOVERY OF BIOMARKERS
    ADOPTION IN PERSONALIZED MEDICINE
  • 5.11 PRICING ANALYSIS
    INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY OFFERING, 2023
    AVERAGE SELLING PRICE TREND, BY REGION (QUALITATIVE)
  • 5.12 KEY CONFERENCES & EVENTS, 2024–2025
  • 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
    BUYING CRITERIA
  • 5.14 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.15 END-USER ANALYSIS
    UNMET NEEDS
    END-USER EXPECTATIONS
  • 5.16 INVESTMENT & FUNDING SCENARIO
  • 5.17 IMPACT OF AI/GEN AI ON BIOSIMULATION MARKET
    KEY USE CASES
    IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    - Case study
    - Bioinformatics market
    - Drug discovery services market
    - Drug discovery informatics market
    USER READINESS & IMPACT ASSESSMENT
    - User readiness
    - Impact assessment
BIOSIMULATION MARKET, BY OFFERING
96
  • 6.1 INTRODUCTION
  • 6.2 SOFTWARE
    STANDALONE MODULES
    - Molecular modeling & simulation software
    - PK/PD modeling & simulation software
    - PBPK modeling & simulation software
    - Toxicity prediction software
    - Clinical trial simulation software
    - Other biosimulation software
    INTEGRATED SOFTWARE SUITES/PLATFORMS
    - Need for efficient R&D tools to accelerate growth of integrated platforms
  • 6.3 SERVICES
    CONSULTING & ADVISORY
    - Need to focus on core competencies to drive need for consulting & advisory services
    IMPLEMENTATION, TRAINING, AND SUPPORT
    - Need for well-trained professionals and experts to accelerate market growth
    DATA ANALYSIS & INTERPRETATION
    - Accurate and precise interpretation of data to drive need for data analysis & interpretation services
BIOSIMULATION MARKET, BY APPLICATION
112
  • 7.1 INTRODUCTION
  • 7.2 DRUG DISCOVERY
    TARGET IDENTIFICATION & VALIDATION
    - Need for identification of optimal targets in drug discovery to drive market
    LEAD IDENTIFICATION & OPTIMIZATION
    - Crucial role in facilitating viable drug discovery to accelerate market growth
  • 7.3 DRUG DEVELOPMENT
    PRECLINICAL TESTING
    - PK/PD
    - ADME/Toxicology
    CLINICAL TRIALS
    - Phase I
    - Phase II
    - Phase III
    - Phase IV/Post-marketing surveillance
  • 7.4 DISEASE MODELING
    CAPABILITY TO PREDICT DISEASE DYNAMICS AND INFORM THERAPEUTIC STRATEGIES TO DRIVE MARKET GROWTH
  • 7.5 MANUFACTURING & SUPPLY CHAIN MANAGEMENT
    PRODUCTION PLANNING & OPTIMIZATION
    - Need for proper production planning and execution to drive market growth
    QUALITY CONTROL & PROCESS MONITORING
    - Adherence to maintaining product quality to fuel market growth
    DEMAND FORECASTING & INVENTORY MANAGEMENT
    - Need to forecast demand effectively to drive market growth
    RISK MANAGEMENT & CONTINGENCY PLANNING
    - Need to maintain operational continuity to support market growth
    OTHER MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS
  • 7.6 OTHER APPLICATIONS
BIOSIMULATION MARKET, BY THERAPEUTIC AREA
136
  • 8.1 INTRODUCTION
  • 8.2 ONCOLOGY
    HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE MARKET GROWTH
  • 8.3 CARDIOVASCULAR DISEASES
    RISING NEED FOR DRUGS TO TREAT CARDIOVASCULAR DISEASES TO BOOST MARKET
  • 8.4 NEUROLOGICAL DISORDERS
    NEED TO BOOST DRUG DISCOVERY AND DEVELOPMENT FOR NEUROLOGICAL DISORDERS TO SUPPORT MARKET GROWTH
  • 8.5 INFECTIOUS DISEASES
    RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY
  • 8.6 OTHER THERAPEUTIC AREAS
BIOSIMULATION MARKET, BY REVENUE MODEL
143
  • 9.1 INTRODUCTION
  • 9.2 LICENSE-BASED MODELS
    LICENSE-BASED MODELS TO ACCOUNT FOR LARGEST SHARE OF MARKET
  • 9.3 SUBSCRIPTION-BASED MODELS
    SUBSCRIPTION-BASED MODELS TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • 9.4 SERVICE-BASED MODELS
    SPECIALIZED SIMULATION EXPERTISE WITH SERVICE-BASED MODELS TO SUPPORT ADOPTION
  • 9.5 PAY-PER-USE MODELS
    RISING DEMAND FOR FLEXIBLE BIOSIMULATION SOLUTIONS WITHOUT UPFRONT COSTS TO SUPPORT MARKET GROWTH
BIOSIMULATION MARKET, BY DEPLOYMENT MODEL
149
  • 10.1 INTRODUCTION
  • 10.2 ON-PREMISE MODELS
    OPTIMAL CONTROL ON DEPLOYMENT AND DATA BACKUP TO SUPPORT MARKET UPTAKE
  • 10.3 CLOUD-BASED MODELS
    CLOUD-BASED MODEL TO EXPERIENCE HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • 10.4 HYBRID MODELS
    BALANCED CAPABILITIES OF HYBRID BIOSIMULATION MODELS TO ACCELERATE ADOPTION
BIOSIMULATION MARKET, BY END USER
154
  • 11.1 INTRODUCTION
  • 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    INCREASING R&D EXPENDITURE FOR DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
  • 11.3 CONTRACT RESEARCH ORGANIZATIONS
    RISING OUTSOURCING OF CLINICAL TRIAL ACTIVITIES TO CROS BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET
  • 11.4 ACADEMIC & RESEARCH INSTITUTES
    FAVORABLE GOVERNMENT SUPPORT FOR RESEARCH TO SUPPORT MARKET GROWTH
  • 11.5 REGULATORY BODIES
    GROWING USAGE OF BIOSIMULATION SOFTWARE FOR CLINICAL TRIAL EFFICACY TO PROPEL MARKET GROWTH
  • 11.6 OTHER END USERS
BIOSIMULATION MARKET, BY REGION
161
  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - Rising government funding for pharmaceutical R&D to drive market
    CANADA
    - Increasing funding by Canadian government in healthcare to drive market
  • 12.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - High number of sponsored clinical trials to drive uptake of biosimulation
    UK
    - Investments by pharmaceutical sponsors for drug discovery services to boost market
    FRANCE
    - Growing R&D pipeline for clinical trials to drive market
    ITALY
    - Increasing government funds and favorable regulatory scenarios to fuel uptake
    SPAIN
    - Established network of research centers to propel market
    REST OF EUROPE
  • 12.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Low cost of drug development and large pharmaceutical R&D base to drive market
    INDIA
    - Growing pharmaceutical industry to fuel uptake of biosimulation
    JAPAN
    - Established drug development infrastructure and biomedical research capabilities to support market growth
    REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Advancing biosimulation in region to support market growth
    MEXICO
    - Government initiatives to enhance digital health to propel market growth
    REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST & AFRICA
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    GCC COUNTRIES
    - Increase in healthcare investments to support market growth
    REST OF MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
289
  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOSIMULATION MARKET
  • 13.3 REVENUE ANALYSIS, 2019–2023
  • 13.4 MARKET SHARE ANALYSIS, 2023
    CERTARA, USA (US)
    DASSAULT SYSTÈMES (FRANCE)
    SCHRÖDINGER, INC. (US)
    SIMULATIONS PLUS (US)
    ADVANCED CHEMISTRY DEVELOPMENT, INC. (CANADA)
  • 13.5 RANKING OF KEY MARKET PLAYERS
  • 13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Offering footprint
    - Application footprint
    - End-user footprint
    - Region footprint
  • 13.7 COMPANY EVALUATION MATRIX: START-UP/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 13.8 COMPANY EVALUATION & FINANCIAL METRICS
  • 13.9 BRAND/PRODUCT COMPARISON
  • 13.10 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES & ENHANCEMENTS
    DEALS
    EXPANSIONS
    OTHER DEVELOPMENTS
COMPANY PROFILES
311
  • 14.1 KEY PLAYERS
    CERTARA, USA
    - Business overview
    - Products & services offered
    - Recent developments
    - MnM view
    DASSAULT SYSTÈMES
    - Business overview
    - Products & services offered
    - Recent developments
    - MnM view
    SCHRÖDINGER, INC.
    - Business overview
    - Products & services offered
    - Recent developments
    - MnM view
    SIMULATIONS PLUS
    - Business overview
    - Products & services offered
    - Recent developments
    ADVANCED CHEMISTRY DEVELOPMENT, INC.
    - Business overview
    - Products & services offered
    - Recent developments
    CHEMICAL COMPUTING GROUP ULC
    - Business overview
    - Products & services offered
    - Recent developments
    ROSA & CO. LLC
    - Business overview
    - Products & services offered
    GENEDATA AG (A DANAHER COMPANY)
    - Business overview
    - Products & services offered
    - Recent developments
    PHYSIOMICS PLC
    - Business overview
    - Products & services offered
    - Recent developments
    IN SILICO BIOSCIENCES
    - Business overview
    - Products & services offered
    ALLUCENT
    - Business overview
    - Products & services offered
    - Recent developments
    OPENEYE, CADENCE MOLECULAR SCIENCES
    - Business overview
    - Products & services offered
    - Recent developments
    CELLWORKS GROUP, INC.
    - Business overview
    - Products & services offered
    - Recent developments
    VERISIM LIFE
    - Business overview
    - Products & services offered
    - Recent developments
    NETABOLICS
    - Business overview
    - Products & services offered
    CHARNWOOD DISCOVERY
    - Business overview
    - Products & services offered
    - Recent developments
    THE MATHWORKS, INC.
    - Business overview
    - Products & services offered
    - Recent developments
    ANSYS, INC.
    - Business overview
    - Products & services offered
  • 14.2 START-UP/SME PLAYERS
    INSTEM GROUP OF COMPANIES
    INSILICO MEDICINE
    SCM – SOFTWARE CHEMISTRY & MATERIALS
    BIOSYMETRICS, INC.
    ATOMWISE INC.
    INSITRO
    CLINITHINK
APPENDIX
368
  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 BIOSIMULATION MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 2 BIOSIMULATION MARKET: PORTER’S FIVE FORCES
  • TABLE 3 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 4 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 5 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 6 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 7 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY OFFERING
  • TABLE 9 BIOSIMULATION MARKET: KEY CONFERENCES AND EVENTS, 2024–2025
  • TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS (%)
  • TABLE 11 KEY BUYING CRITERIA FOR TOP 3 END USERS
  • TABLE 12 UNMET NEEDS IN BIOSIMULATION MARKET
  • TABLE 13 END-USER EXPECTATIONS IN BIOSIMULATION MARKET
  • TABLE 14 BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 15 BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 16 BIOSIMULATION SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 17 BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 18 BIOSIMULATION MARKET FOR STANDALONE MODULES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 19 BIOSIMULATION MARKET FOR MOLECULAR MODELING & SIMULATION SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 20 BIOSIMULATION MARKET FOR PK/PD MODELING & SIMULATION SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 21 BIOSIMULATION MARKET FOR PBPK MODELING & SIMULATION SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 22 BIOSIMULATION MARKET FOR TOXICITY PREDICTION SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 23 BIOSIMULATION MARKET FOR CLINICAL TRIAL SIMULATION SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 24 BIOSIMULATION MARKET FOR OTHER BIOSIMULATION SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 25 BIOSIMULATION MARKET FOR INTEGRATED SOFTWARE SUITES/PLATFORMS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 26 BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 27 BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 28 BIOSIMULATION MARKET FOR CONSULTING & ADVISORY SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 29 BIOSIMULATION MARKET FOR IMPLEMENTATION, TRAINING, AND SUPPORT SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 30 BIOSIMULATION MARKET FOR DATA ANALYSIS & INTERPRETATION SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 31 BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 32 BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 33 BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 34 BIOSIMULATION MARKET FOR TARGET IDENTIFICATION & VALIDATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 35 BIOSIMULATION MARKET FOR LEAD IDENTIFICATION & OPTIMIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 36 BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 37 BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 38 BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 39 BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 40 BIOSIMULATION MARKET FOR PK/PD, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 41 BIOSIMULATION MARKET FOR ADME/TOXICOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 42 BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 43 BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY COUNTRY,2022–2029 (USD MILLION)
  • TABLE 44 BIOSIMULATION MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY,2022–2029 (USD MILLION)
  • TABLE 45 BIOSIMULATION MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY,2022–2029 (USD MILLION)
  • TABLE 46 BIOSIMULATION MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 47 BIOSIMULATION MARKET FOR PHASE IV/POST-MARKETING SURVEILLANCE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 48 BIOSIMULATION MARKET FOR DISEASE MODELING APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 49 BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 50 BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 51 BIOSIMULATION MARKET FOR PRODUCTION PLANNING & OPTIMIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 52 BIOSIMULATION MARKET FOR QUALITY CONTROL & PROCESS MONITORING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 53 BIOSIMULATION MARKET FOR DEMAND FORECASTING & INVENTORY MANAGEMENT, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 54 BIOSIMULATION MARKET FOR RISK MANAGEMENT & CONTINGENCY PLANNING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 55 BIOSIMULATION MARKET FOR OTHER MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 56 BIOSIMULATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 57 BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 58 BIOSIMULATION MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 59 BIOSIMULATION MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 60 BIOSIMULATION MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 61 BIOSIMULATION MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 62 BIOSIMULATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 63 BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 64 BIOSIMULATION MARKET FOR LICENSE-BASED MODELS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 65 BIOSIMULATION MARKET FOR SUBSCRIPTION-BASED MODELS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 66 BIOSIMULATION MARKET FOR SERVICE-BASED MODELS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 67 BIOSIMULATION MARKET FOR PAY-PER-USE MODELS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 68 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 69 BIOSIMULATION MARKET FOR ON-PREMISE MODELS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 70 BIOSIMULATION MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 71 BIOSIMULATION MARKET FOR HYBRID MODELS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 72 BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 73 BIOSIMULATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 74 BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 75 BIOSIMULATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 76 BIOSIMULATION MARKET FOR REGULATORY BODIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 77 BIOSIMULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 78 BIOSIMULATION MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 79 NORTH AMERICA: BIOSIMULATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 80 NORTH AMERICA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 81 NORTH AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 82 NORTH AMERICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 83 NORTH AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 84 NORTH AMERICA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 85 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 86 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 87 NORTH AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 88 NORTH AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 89 NORTH AMERICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 90 NORTH AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 91 NORTH AMERICA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 92 NORTH AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 93 NORTH AMERICA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 94 US: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 95 US: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 96 US: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 97 US: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 98 US: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 99 US: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 100 US: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 101 US: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 102 US: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 103 US: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 104 US: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 105 US: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 106 US: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 107 US: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 108 CANADA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 109 CANADA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 110 CANADA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 111 CANADA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 112 CANADA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 113 CANADA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 114 CANADA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 115 CANADA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 116 CANADA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 117 CANADA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 118 CANADA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 119 CANADA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 120 CANADA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,2022–2029 (USD MILLION)
  • TABLE 121 CANADA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 122 EUROPE: BIOSIMULATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 123 EUROPE: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 124 EUROPE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 125 EUROPE: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 126 EUROPE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 127 EUROPE: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 128 EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 129 EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 130 EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 131 EUROPE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,2022–2029 (USD MILLION)
  • TABLE 132 EUROPE: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 133 EUROPE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 134 EUROPE: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 135 EUROPE: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 136 EUROPE: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 137 GERMANY: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 138 GERMANY: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 139 GERMANY: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 140 GERMANY: BIOSIMULATION SERVICES MARKET, BY TYPE,2022–2029 (USD MILLION)
  • TABLE 141 GERMANY: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 142 GERMANY: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 143 GERMANY: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 144 GERMANY: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 145 GERMANY: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 146 GERMANY: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 147 GERMANY: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,2022–2029 (USD MILLION)
  • TABLE 148 GERMANY: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 149 GERMANY: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 150 GERMANY: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 151 UK: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 152 UK: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 153 UK: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 154 UK: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 155 UK: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 156 UK: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 157 UK: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 158 UK: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 159 UK: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,2022–2029 (USD MILLION)
  • TABLE 160 UK: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 161 UK: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 162 UK: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 163 UK: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 164 UK: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 165 FRANCE: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 166 FRANCE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 167 FRANCE: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 168 FRANCE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 169 FRANCE: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 170 FRANCE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 171 FRANCE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 172 FRANCE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 173 FRANCE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 174 FRANCE: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 175 FRANCE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,2022–2029 (USD MILLION)
  • TABLE 176 FRANCE: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 177 FRANCE: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 178 FRANCE: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 179 ITALY: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 180 ITALY: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 181 ITALY: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 182 ITALY: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 183 ITALY: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 184 ITALY: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 185 ITALY: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 186 ITALY: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 187 ITALY: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 188 ITALY: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 189 ITALY: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 190 ITALY: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 191 ITALY: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 192 ITALY: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 193 SPAIN: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 194 SPAIN: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 195 SPAIN: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 196 SPAIN: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 197 SPAIN: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 198 SPAIN: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 199 SPAIN: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 200 SPAIN: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 201 SPAIN: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 202 SPAIN: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 203 SPAIN: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 204 SPAIN: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 205 SPAIN: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,2022–2029 (USD MILLION)
  • TABLE 206 SPAIN: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 207 REST OF EUROPE: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 208 REST OF EUROPE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 209 REST OF EUROPE: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 210 REST OF EUROPE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 211 REST OF EUROPE: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 212 REST OF EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 213 REST OF EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 214 REST OF EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 215 REST OF EUROPE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 216 REST OF EUROPE: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 217 REST OF EUROPE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 218 REST OF EUROPE: BIOSIMULATION MARKET, BY REVENUE MODEL,2022–2029 (USD MILLION)
  • TABLE 219 REST OF EUROPE: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 220 REST OF EUROPE: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 221 ASIA PACIFIC: BIOSIMULATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 222 ASIA PACIFIC: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 223 ASIA PACIFIC: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 224 ASIA PACIFIC: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 225 ASIA PACIFIC: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 226 ASIA PACIFIC: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 227 ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 228 ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 229 ASIA PACIFIC: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 230 ASIA PACIFIC: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 231 ASIA PACIFIC: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 232 ASIA PACIFIC: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 233 ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 234 ASIA PACIFIC: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 235 ASIA PACIFIC: BIOSIMULATION MARKET, BY END USER,2022–2029 (USD MILLION)
  • TABLE 236 CHINA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 237 CHINA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 238 CHINA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 239 CHINA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 240 CHINA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 241 CHINA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 242 CHINA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 243 CHINA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 244 CHINA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 245 CHINA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 246 CHINA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 247 CHINA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 248 CHINA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 249 CHINA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 250 INDIA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 251 INDIA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 252 INDIA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 253 INDIA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 254 INDIA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 255 INDIA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 256 INDIA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 257 INDIA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 258 INDIA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 259 INDIA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 260 INDIA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 261 INDIA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 262 INDIA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 263 INDIA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 264 JAPAN: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 265 JAPAN: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 266 JAPAN: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 267 JAPAN: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 268 JAPAN: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 269 JAPAN: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 270 JAPAN: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 271 JAPAN: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 272 JAPAN: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 273 JAPAN: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 274 JAPAN: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 275 JAPAN: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 276 JAPAN: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 277 JAPAN: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 278 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 279 REST OF ASIA PACIFIC: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 280 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 281 REST OF ASIA PACIFIC: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 282 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 283 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 284 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 285 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 286 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 287 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 288 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 289 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 290 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 291 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 292 LATIN AMERICA: BIOSIMULATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 293 LATIN AMERICA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 294 LATIN AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE,2022–2029 (USD MILLION)
  • TABLE 295 LATIN AMERICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 296 LATIN AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 297 LATIN AMERICA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 298 LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 299 LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 300 LATIN AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 301 LATIN AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 302 LATIN AMERICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 303 LATIN AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 304 LATIN AMERICA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 305 LATIN AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 306 LATIN AMERICA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 307 BRAZIL: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 308 BRAZIL: BIOSIMULATION SOFTWARE MARKET, BY TYPE,2022–2029 (USD MILLION)
  • TABLE 309 BRAZIL: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 310 BRAZIL: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 311 BRAZIL: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 312 BRAZIL: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 313 BRAZIL: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 314 BRAZIL: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 315 BRAZIL: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 316 BRAZIL: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 317 BRAZIL: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 318 BRAZIL: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 319 BRAZIL: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 320 BRAZIL: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 321 MEXICO: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 322 MEXICO: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 323 MEXICO: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 324 MEXICO: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 325 MEXICO: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 326 MEXICO: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 327 MEXICO: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 328 MEXICO: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 329 MEXICO: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 330 MEXICO: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 331 MEXICO: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 332 MEXICO: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 333 MEXICO: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 334 MEXICO: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 335 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 336 REST OF LATIN AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 337 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 338 REST OF LATIN AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 339 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 340 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 341 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 342 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 343 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 344 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 345 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 346 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 347 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 348 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 349 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY COUNTRY,2022–2029 (USD MILLION)
  • TABLE 350 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 351 MIDDLE EAST & AFRICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 352 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 353 MIDDLE EAST & AFRICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 354 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 355 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 356 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 357 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 358 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 359 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 360 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 361 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 362 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 363 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 364 GCC COUNTRIES: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 365 GCC COUNTRIES: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 366 GCC COUNTRIES: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 367 GCC COUNTRIES: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 368 GCC COUNTRIES: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 369 GCC COUNTRIES: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 370 GCC COUNTRIES: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 371 GCC COUNTRIES: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 372 GCC COUNTRIES: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 373 GCC COUNTRIES: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 374 GCC COUNTRIES: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 375 GCC COUNTRIES: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 376 GCC COUNTRIES: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 377 GCC COUNTRIES: BIOSIMULATION MARKET, BY END USER,2022–2029 (USD MILLION)
  • TABLE 378 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 379 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 380 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 381 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 382 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 383 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 384 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 385 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 386 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 387 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 388 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 389 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 390 REST OF MIDDLE EAST & AFRICA NORTH AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 391 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 392 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSIMULATION MARKET
  • TABLE 393 BIOSIMULATION MARKET: DEGREE OF COMPETITION
  • TABLE 394 BIOSIMULATION MARKET: OFFERING FOOTPRINT
  • TABLE 395 BIOSIMULATION MARKET: APPLICATION FOOTPRINT
  • TABLE 396 BIOSIMULATION MARKET: END-USER FOOTPRINT
  • TABLE 397 BIOSIMULATION MARKET: REGION FOOTPRINT
  • TABLE 398 BIOSIMULATION MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • TABLE 399 BIOSIMULATION MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 400 BIOSIMULATION MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 401 BIOSIMULATION MARKET: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 402 BIOSIMULATION MARKET: EXPANSIONS, JANUARY 2021–OCTOBER 2024
  • TABLE 403 BIOSIMULATION MARKET: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 404 CERTARA, USA: COMPANY OVERVIEW
  • TABLE 405 CERTARA, USA: PRODUCTS & SERVICES OFFERED
  • TABLE 406 CERTARA, USA: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021−OCTOBER 2024
  • TABLE 407 CERTARA, USA: DEALS, JANUARY 2021−OCTOBER 2024
  • TABLE 408 DASSAULT SYSTÈMES: COMPANY OVERVIEW
  • TABLE 409 DASSAULT SYSTÈMES: PRODUCTS & SERVICES OFFERED
  • TABLE 410 DASSAULT SYSTÈMES: DEALS, JANUARY 2021−JUNE 2024
  • TABLE 411 SCHRÖDINGER, INC.: COMPANY OVERVIEW
  • TABLE 412 SCHRÖDINGER, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 413 SCHRÖDINGER, INC.: DEALS, JANUARY 2021−OCTOBER 2024
  • TABLE 414 SIMULATIONS PLUS: COMPANY OVERVIEW
  • TABLE 415 SIMULATIONS PLUS: PRODUCTS & SERVICES OFFERED
  • TABLE 416 SIMULATIONS PLUS: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021−OCTOBER 2024
  • TABLE 417 SIMULATIONS PLUS: DEALS, JANUARY 2021−OCTOBER 2024
  • TABLE 418 SIMULATIONS PLUS: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 419 ADVANCED CHEMISTRY DEVELOPMENT, INC.: COMPANY OVERVIEW
  • TABLE 420 ADVANCED CHEMISTRY DEVELOPMENT, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 421 ADVANCED CHEMISTRY DEVELOPMENT, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021−OCTOBER 2024
  • TABLE 422 ADVANCED CHEMISTRY DEVELOPMENT, INC.: DEALS, JANUARY 2021−OCTOBER 2024
  • TABLE 423 CHEMICAL COMPUTING GROUP ULC: COMPANY OVERVIEW
  • TABLE 424 CHEMICAL COMPUTING GROUP ULC: PRODUCTS & SERVICES OFFERED
  • TABLE 425 CHEMICAL COMPUTING GROUP ULC: DEALS, JANUARY 2021−OCTOBER 2024
  • TABLE 426 ROSA & CO. LLC: COMPANY OVERVIEW
  • TABLE 427 ROSA & CO. LLC: PRODUCTS & SERVICES OFFERED
  • TABLE 428 GENEDATA AG (A DANAHER COMPANY): COMPANY OVERVIEW
  • TABLE 429 GENEDATA AG (A DANAHER COMPANY): PRODUCTS & SERVICES OFFERED
  • TABLE 430 GENEDATA AG (A DANAHER COMPANY): PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021−OCTOBER 2024
  • TABLE 431 GENEDATA AG (A DANAHER COMPANY): DEALS, JANUARY 2021−OCTOBER 2024
  • TABLE 432 PHYSIOMICS PLC: COMPANY OVERVIEW
  • TABLE 433 PHYSIOMICS PLC: PRODUCTS & SERVICES OFFERED
  • TABLE 434 PHYSIOMICS PLC: DEALS, JANUARY 2021−OCTOBER 2024
  • TABLE 435 IN SILICO BIOSCIENCES: COMPANY OVERVIEW
  • TABLE 436 IN SILICO BIOSCIENCES: PRODUCTS & SERVICES OFFERED
  • TABLE 437 ALLUCENT: COMPANY OVERVIEW
  • TABLE 438 ALLUCENT: PRODUCTS & SERVICES OFFERED
  • TABLE 439 ALLUCENT: DEALS, JANUARY 2021−OCTOBER 2024
  • TABLE 440 ALLUCENT: EXPANSIONS, JANUARY 2021–OCTOBER 2024
  • TABLE 441 OPENEYE, CADENCE MOLECULAR SCIENCES: COMPANY OVERVIEW
  • TABLE 442 OPENEYE, CADENCE MOLECULAR SCIENCES: PRODUCTS & SERVICES OFFERED
  • TABLE 443 OPENEYE, CADENCE MOLECULAR SCIENCES: PRODUCT ENHANCEMENTS, JANUARY 2021−OCTOBER 2024
  • TABLE 444 OPENEYE, CADENCE MOLECULAR SCIENCES: DEALS, JANUARY 2021−OCTOBER 2024
  • TABLE 445 OPENEYE, CADENCE MOLECULAR SCIENCES: EXPANSIONS, JANUARY 2021–OCTOBER 2024
  • TABLE 446 CELLWORKS GROUP, INC.: COMPANY OVERVIEW
  • TABLE 447 CELLWORKS GROUP, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 448 CELLWORKS GROUP, INC.: EXPANSIONS, JANUARY 2021–OCTOBER 2024
  • TABLE 449 VERISIM LIFE: COMPANY OVERVIEW
  • TABLE 450 VERISIM LIFE: PRODUCTS & SERVICES OFFERED
  • TABLE 451 VERISIM LIFE: DEALS, JANUARY 2021−OCTOBER 2024
  • TABLE 452 VERISIM LIFE: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 453 NETABOLICS: COMPANY OVERVIEW
  • TABLE 454 NETABOLICS: PRODUCTS & SERVICES OFFERED
  • TABLE 455 CHARNWOOD DISCOVERY: COMPANY OVERVIEW
  • TABLE 456 CHARNWOOD DISCOVERY: PRODUCTS & SERVICES OFFERED
  • TABLE 457 CHARNWOOD DISCOVERY: DEALS, JANUARY 2021−OCTOBER 2024
  • TABLE 458 THE MATHWORKS, INC.: COMPANY OVERVIEW
  • TABLE 459 THE MATHWORKS, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 460 THE MATHWORKS, INC.: PRODUCT ENHANCEMENTS, JANUARY 2021−OCTOBER 2024
  • TABLE 461 ANSYS, INC.: COMPANY OVERVIEW
  • TABLE 462 ANSYS, INC.: PRODUCTS & SERVICES OFFERED
LIST OF FIGURES
 
  • FIGURE 1 BIOSIMULATION MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 PRIMARY SOURCES
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 6 TOP-DOWN APPROACH
  • FIGURE 7 CAGR PROJECTIONS, 2024–2029
  • FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 9 DATA TRIANGULATION
  • FIGURE 10 BIOSIMULATION MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
  • FIGURE 11 BIOSIMULATION MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 BIOSIMULATION MARKET, BY REVENUE MODEL, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 BIOSIMULATION MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 GEOGRAPHIC SNAPSHOT OF BIOSIMULATION MARKET
  • FIGURE 17 INCREASING R&D EXPENDITURE ON DRUG DISCOVERY & DEVELOPMENT BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DRIVE MARKET
  • FIGURE 18 CHINA DOMINATED MARKET IN ASIA PACIFIC IN 2023
  • FIGURE 19 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 20 NORTH AMERICA TO DOMINATE BIOSIMULATION MARKET DURING FORECAST PERIOD
  • FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
  • FIGURE 22 BIOSIMULATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 23 BIOSIMULATION MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 24 BIOSIMULATION MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 25 BIOSIMULATION MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 26 PATENT PUBLICATION TRENDS IN BIOSIMULATION MARKET, 2015–2024
  • FIGURE 27 BIOSIMULATION MARKET: PATENT ANALYSIS, JANUARY 2015–SEPTEMBER 2024
  • FIGURE 28 INDICATIVE PRICING ANALYSIS FOR BIOSIMULATION SOFTWARE
  • FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS
  • FIGURE 30 KEY BUYING CRITERIA FOR TOP 3 END USERS
  • FIGURE 31 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • FIGURE 32 BIOSIMULATION MARKET: INVESTMENT & FUNDING SCENARIO
  • FIGURE 33 MARKET POTENTIAL OF AI/GENERATIVE AI ON BIOSIMULATION
  • FIGURE 34 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
  • FIGURE 35 NORTH AMERICA: BIOSIMULATION MARKET SNAPSHOT
  • FIGURE 36 ASIA PACIFIC: BIOSIMULATION MARKET SNAPSHOT
  • FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN BIOSIMULATION MARKET, 2019–2023 (USD BILLION)
  • FIGURE 38 BIOSIMULATION MARKET: MARKET SHARE ANALYSIS (2023)
  • FIGURE 39 RANKING OF KEY PLAYERS IN BIOSIMULATION MARKET, 2023
  • FIGURE 40 BIOSIMULATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 41 BIOSIMULATION MARKET: COMPANY FOOTPRINT
  • FIGURE 42 BIOSIMULATION MARKET: COMPANY EVALUATION MATRIX(START-UPS/SMES), 2023
  • FIGURE 43 EV/EBITDA OF KEY VENDORS
  • FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF BIOSIMULATION VENDORS
  • FIGURE 45 BIOSIMULATION MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 46 CERTARA, USA: COMPANY SNAPSHOT (2023)
  • FIGURE 47 DASSAULT SYSTÈMES: COMPANY SNAPSHOT (2023)
  • FIGURE 48 SCHRÖDINGER, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 49 SIMULATIONS PLUS: COMPANY SNAPSHOT (2023)
  • FIGURE 50 GENEDATA AG (A DANAHER COMPANY): COMPANY SNAPSHOT (2023)
  • FIGURE 51 PHYSIOMICS PLC: COMPANY SNAPSHOT (2023)
  • FIGURE 52 OPENEYE, CADENCE MOLECULAR SCIENCES: COMPANY SNAPSHOT (2023)
  • FIGURE 53 ANSYS, INC.: COMPANY SNAPSHOT (2023)

The study involved significant activities to estimate the current size of the Biosimulation market. Exhaustive secondary research was done to collect information on the biosimulation market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the biosimulation market.

Secondary Research

This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering biosimulation solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of biosimulation vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

Primary Research

In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the biosimulation market.

After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of Biosimulation solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.

In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

Breakdown of Primary Participants:

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the Biosimulation market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research.
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Data Triangulation

After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Biosimulation is a computer-aided mathematical modeling to simulate the functioning of the human body and analyze the effects of drugs, both beneficial and adverse. By creating a virtual model of physiological processes, researchers can investigate disease progression and evaluate the potential impact of various therapeutic interventions. This technology enables the simulation of real-world biological interactions, facilitating the testing of multiple scenarios and optimizing the development of safer, more effective drugs and treatments.

Stakeholders

  • Biosimulation Vendors
  • Contract Research Organizations
  • Pharmaceutical/Biopharmaceutical Companies
  • Research and Development (R&D) Companies
  • Business Research and Consulting Service Providers
  • Medical Research Laboratories
  • Academic Medical Centers/Universities/Hospitals
  • Government Agencies
  • Regulatory Agencies
  • Clinical Researchers
  • Clinical Research Organizations
  • Investors and Venture Capitalists

Report Objectives

  • To define, describe, and forecast the biosimulation market based on offerings, applications, therapeutic area, revenue model, deployment model, end user, and region
  • To provide detailed information about the major factors (drivers, opportunities, restraints, and challenges) influencing the growth of the market
  • To analyze opportunities for stakeholders by identifying the high-growth segments of the market
  • To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
  • To analyze subsegments of the market with respect to individual growth trends, prospects, and contributions to the overall market
  • To profile the key players and comprehensively analyze their market sizes and core competencies
  • To track and analyze competitive developments such as acquisitions, collaborations, agreements, mergers, product launches & updates, partnerships, expansions, and other recent developments in the market globally

Previous Versions of this Report

Biosimulation Market by Product (Software, Molecular Simulation, In House, Contract Services), Application (Clinical Trials, PKPD, ADME), Delivery (Subscription, Ownership), End User (Biotech, Pharma Companies, CROs, Regulatory) - Global Forecast to 2022

Report Code HIT 3629
Published in Jan, 2018, By MarketsandMarkets™

Global Biosimulation Technology Market (For Drug Discovery & Development) (2012 – 2017)

Report Code HIT 3629
Published in Jul, 2015, By MarketsandMarkets™

Global Biosimulation Technology Market (For Drug Discovery & Development) (2012 – 2017)

Report Code PH 1301
Published in Oct, 2012, By MarketsandMarkets™

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Biosimulation Market

+1-888600-6441

Corporate Office Hours

+1-888600-6441

US/Can Toll Free

+44-800-368-9399

UK Office Hours

©2024 Marketsandmarkets Research Private Ltd. All Rights Reserved.

DMCA.com Protection Status